Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab

Figures & data

Table 1. Clinical data of six AD cases.

Patient No.	Age, Gender	Duration of AD (Years)	Personal atopic history	Previous treatment method	Treatment	Duration of Upadacitinib (Weeks)	Complications
1	14, female	10	None	Dupilumab 16 weeks + Topical medications	Upadacitinib 15 mg/day	12	None
2	15, male	9	None	Dupilumab 14 weeks + Topical medications	Upadacitinib 15 mg/day	12	None
3	16, male	12	None	Dupilumab 14 weeks + Topical medications	Upadacitinib 15 mg/day	12	None
4	35, female	15	Allergic rhinitis	Dupilumab 18 weeks + Topical medications	Upadacitinib 15 mg/day	12	None
5	12, male	10	None	Dupilumab 16 weeks + Topical medications	Upadacitinib 15 mg/day	12	None
6	20, female	19	None	Dupilumab 20 weeks + Topical medications	Upadacitinib 15 mg/day	12	None

Figure 1. (A, B) Face and neck lesions before treatment with dupilumab. (C, D) no significant improvement in the skin lesions of the face and neck after 12 weeks of dupilumab treatment. (E, F) Clinical improvement after 4 weeks of upadacitinib. (G, H) Marked improvement with clearing of face and neck lesions after 8 weeks of upadacitinib. (I, J) Clinical complete resolution after 12 weeks with upadacitinib without recurrence.

Table 2. Summary of the treatment efficacy of upadacitinib after 12 weeks of treatment.

Category	Before Upadacitinib Treatment	4 week	8 week	12 week	P
EASI	8.1 ± 0.66	3.95 ± 0.75	1.9 ± 0.89	0.73 ± 0.56	<0.001
DLQI	12.5 ± 6.24	3.83 ± 1.07	1.67 ± 0.75	0.67 ± 0.75	<0.001
ADCT	11.5 ± 3.15	4 ± 2.71	2.33 ± 2.36	0.33 ± 0.75	<0.001
P-NRS	6.83 ± 0.37	2 ± 1	0.67 ± 0.47	0	0.0001
IgE (IU/mL)	3855.05 ± 3990.98			3083.12 ± 3066.23	0.5213
Eosinophils count (×109 /L)	2.65 ± 3.24			1.42 ± 2.42	0.0375
IL-4 (pg/ml)	6.83 ± 3.79			5.28 ± 3.42	0.0024
IL-5 (pg/ml)	1.27 ± 1.1			1.14 ± 0.62	0.8239
IL-13 (pg/ml)	1.84 ± 2.3			1.44 ± 1.16	0.7426
IL-17 (pg/ml)	0.46 ± 0.23			1.73 ± 0.76	0.0082
IL-22 (pg/ml)	0.38 ± 0.16			0.28 ± 0.04	0.1547
IL-31 (pg/ml)	5.11 ± 2.68			2.83 ± 1.37	0.0426
IFN-ƴ (pg/ml)	2.06 ± 2.86			1.46 ± 1.56	0.4003

Note: EASI, Eczema Area Severity Index (range: 0–72); DLQI, Dermatology Life Quality Index (range: 0–30); ADCT, Atopic Dermatitis control tool (range: 0-24); P-NRS, Pruritus Numerical Rating Scale (range: 0–10).